Replimune Group

Explore Replimune clinical trials studying the future of oncolytic immunotherapy.

Replimune provides research and educational support for medical professionals on its oncolytic immunotherapies.

Replimune offers oncolytic immunotherapies, including TUDRIQEV for melanoma resistant to anti-PD1 therapy.

Replimune’s RPx platform includes clinical and commercial pipelines for oncolytic immunotherapies.

Replimune highlights career opportunities, company values, and workplace culture.

Meet the team of innovative leaders in research, development, and commercialization pioneering the next generation of oncolytic immunotherapies.

Replimune develops oncolytic immunotherapies to trigger a systemic immune response and address cancer treatment.

Replimune handles media, investor, and clinical trial inquiries.

Replimune advances cancer treatment with oncolytic immunotherapies designed to activate a systemic immune response.

Replimune delivers its immunotherapy drug **Tudriqev** to patients with advanced melanoma. The company reports fiscal second-quarter 2027 financial results alongside a corporate update, highlighting progress in its clinical pipeline and operational milestones.

Oct 2026Replimune Group Inc.News article

Replimune Group makes TUDRIQEV™ (vusolimogene oderparepvec-wtpg) available in the U.S. as a treatment for adult patients with unresectable advanced cutaneous melanoma whose disease progressed after prior therapy. The oncolytic immunotherapy is approved for use in combination with nivolumab. Replimune specializes in developing novel cancer immunotherapies.

Oct 2026Replimune Group Inc.News article

Replimune secures FDA accelerated approval for **TUDRIQEV™** in combination with **nivolumab**, a checkpoint inhibitor. The therapy targets cancer treatment and will launch commercially within 60 days. The company updates investors on fiscal Q1 2027 financial performance alongside this regulatory milestone.

Aug 2026Replimune Group Inc.News article

Replimune priced a $150 million underwritten offering of 9.7 million shares at $12.06 per share. The deal includes pre-funded warrants for 2.7 million additional shares at $12.06, issued to certain investors instead of common stock. The company develops oncolytic immunotherapies for cancer treatment.

Aug 2026Replimune Group Inc.News article